RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $451
RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $451
RBC資本維持對福泰製藥的板塊表現,並將價格目標上調至451美元
RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sector Perform and raises the price target from $437 to $451.
RBC資本分析師布萊恩·亞伯拉罕維持Sector Perform評級,將福泰製藥(納斯達克:VRTX)的目標股價從437美元上調至451美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。